{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Janssen+Inc.",
    "query": {
      "sponsor": "Janssen Inc.",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 62,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Janssen+Inc.&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Janssen+Inc.&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T08:33:59.408Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02141425",
      "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Pharmacokinetics of ASP015K"
      ],
      "interventions": [
        {
          "name": "ASP015K",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2014-03",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-06-04",
      "last_synced_at": "2026-10-08T08:33:59.408Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02141425"
    },
    {
      "nct_id": "NCT02309580",
      "title": "Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-cell Lymphoma",
        "Relapsed and Refractory T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-01",
      "completion_date": "2023-05-08",
      "has_results": false,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-10-08T08:33:59.408Z",
      "location_count": 2,
      "location_summary": "New York, New York • Columbus, Ohio",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02309580"
    },
    {
      "nct_id": "NCT00257010",
      "title": "A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Almotriptan Malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen-Ortho LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 447,
      "start_date": "2005-12",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2014-02-21",
      "last_synced_at": "2026-10-08T08:33:59.408Z",
      "location_count": 49,
      "location_summary": "Mobile, Alabama • Montgomery, Alabama • Oxford, Alabama + 46 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Oxford",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00257010"
    },
    {
      "nct_id": "NCT00855361",
      "title": "A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastroesophageal Reflux"
      ],
      "interventions": [
        {
          "name": "Rabeprazole sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "44 Weeks",
        "sex": "ALL",
        "summary": "Up to 44 Weeks"
      },
      "enrollment_count": 69,
      "start_date": "2009-07",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-04-29",
      "last_synced_at": "2026-10-08T08:33:59.408Z",
      "location_count": 10,
      "location_summary": "Orange, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00855361"
    },
    {
      "nct_id": "NCT04116164",
      "title": "Safety and Targeting of Anti-hk2 Antibody in mCRPC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Castration-Resistant Prostatic Cancer",
        "Metastatic Disease"
      ],
      "interventions": [
        {
          "name": "111In-DOTA-h11B6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpectronRX",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2019-09-18",
      "completion_date": "2023-07-06",
      "has_results": false,
      "last_update_posted_date": "2023-09-25",
      "last_synced_at": "2026-10-08T08:33:59.408Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04116164"
    },
    {
      "nct_id": "NCT02103361",
      "title": "Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Psoriasis",
        "Pregnancy",
        "Psoriatic Arthritis",
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Guselkumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 200,
      "start_date": "2013-11",
      "completion_date": "2031-02",
      "has_results": false,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-10-08T08:33:59.408Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02103361"
    },
    {
      "nct_id": "NCT03902951",
      "title": "Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Adenocarcinoma",
        "Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation",
        "Recurrent Prostate Carcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 28,
      "start_date": "2021-03-17",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-08T08:33:59.408Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03902951"
    },
    {
      "nct_id": "NCT01190839",
      "title": "A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Infliximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 297,
      "start_date": "2010-11",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-02-04",
      "last_synced_at": "2026-10-08T08:33:59.408Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Orange, California + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01190839"
    },
    {
      "nct_id": "NCT03732703",
      "title": "Myeloma-Developing Regimens Using Genomics (MyDRUG)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Abemaciclib, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Enasidenib, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Erdafitinib, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Selinexor, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Multiple Myeloma Research Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2019-04-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-10-08T08:33:59.408Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03732703"
    },
    {
      "nct_id": "NCT01959399",
      "title": "Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects",
        "Pharmacokinetics of ASP015K"
      ],
      "interventions": [
        {
          "name": "ASP015K",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2013-05",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-10-10",
      "last_synced_at": "2026-10-08T08:33:59.408Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01959399"
    }
  ]
}